Apply now to engage with experts in the field of pancreatic cancer (PCA) by joining this highly interactive 1.5-day live meeting. Our multidisciplinary experts will provide a comprehensive update on the management of PCA, focusing on recent developments for patients with resectable, unresectable, and metastatic PCA as well as supportive care and adverse event management. This exciting meeting will use the following strategies:
- Didactic presentations
- Case-based presentations and clinical management discussions
- Quiz questions
- Q & A sessions
Date and Location
Friday and Saturday
28 – 29 September 2018
Linke Wienzeile/Ullmannstrasse 71
Travel Grant Information
To apply for a travel grant, click on the Apply Now button.
28 – 29 September 2018
Friday, 28 September—Day 1
|19.00||Welcome, introduction, and demographics
Philip Agop Philip, MD, PhD, FRCP, Thomas Seufferlein, MD, PhD, and Eric Van Cutsem, MD, PhD
|19.20||PCA management: Why is it so challenging?
Gerald Prager, MD
|19.45||Audience questions and faculty panel commentary|
|19.55||Clinical case: The value of a multidisciplinary treatment approach in PCA
Thomas Seufferlein, MD, PhD
|20.35||Audience questions and faculty panel commentary|
Saturday, 29 September—Day 2
|08.30||Introduction and objectives of Day 2|
Session I: Improving Outcomes in Patients With Resectable/Borderline Resectable PCA
Moderator: Eric Van Cutsem, MD, PhD
|08.35||The role of radiologist in the multidisciplinary team: Defining resectability of PCA and beyond
Maria Antonietta Bali, MD, PhD
|08.55||Contemporary management of resectable/borderline resectable PCA: Surgery or neoadjuvant therapy first?
Massimo Falconi, MD
|09.20||Optimizing adjuvant therapy in PCA: Impact of new data
Eric Van Cutsem, MD, PhD
|09.40||Ask the experts|
|10.00||Interactive clinical case and multidisciplinary tumor board discussion
Derek O’Reilly, PhD, FRCS
Session II: Multimodality Treatment of Locally Advanced PCA
Moderator: Thomas Seufferlein, MD, PhD
|11.00||Systemic therapy for locally advanced PCA
Stefano Cascinu, MD, PhD
|11.20||Update on locoregional treatment approaches for PCA
Thomas Brunner, MD
|11.40||Ask the experts|
|11.50||Interactive clinical case and multidisciplinary tumor board discussion
Kalliopi Andrikou, MD
|12.10||Supportive care measures throughout the patient’s cancer journey
Matti Aapro, MD
|12.30||Ask the experts|
Session III: Fine-Tuning Continuum of Care in Metastatic Pancreatic Cancer (mPCA)
Moderator: Philip Agop Philip, MD, PhD, FRCP
|13.40||Individualizing systemic therapy for mPCA across the disease continuum
Teresa Macarulla, MD, PhD
|14.00||Ask the experts|
|14.10||Targeted therapy in mPCA: Are we moving forward?
Philip Agop Philip, MD, PhD, FRCP
|14.35||Ask the experts|
|14.45||Interactive clinical cases and multidisciplinary tumor board discussion
Alicia Beutel, MD, and Helena Verdaguer, MD
|15.25||Brain teasers revisited and faculty commentary|
|15.40||prIME Points™ and what to expect in PCA management in the coming years
Thomas Seufferlein, MD, PhD
Philip Agop Philip, MD, PhD, FRCPWayne State University and Karmanos Cancer Institute
Detroit, Michigan, United States
Thomas Seufferlein, MD, PhD University of Ulm
Eric Van Cutsem, MD, PhDUniversity Hospitals Leuven
Matti Aapro, MDMultidisciplinary Oncology Institute
Maria Antonietta Bali, MD, PhDInstitut Jules Bordet
Free University of Brussels
Thomas Brunner, MD, PhDUniversity Medical Center Freiburg
Stefano Cascinu, MD, PhDUniversity of Modena and Reggio Emilia
Massimo Falconi, MDUniversity Vita-Salute San Raffaele
IRCCS San Raffaele Hospital
Teresa Macarulla, MD, PhDVall d’Hebron University Hospital
Gerald Prager, MDMedical University of Vienna
This educational activity is designed for European gastroenterologists, surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with PCA.
After successful completion of this educational activity, participants should be able to:
- Identify risk factors for PCA and discuss reasons for poor outcomes and treatment resistance, including genetic diversity and role of PCA stroma
- Recognize imaging criteria for resectability of PCA
- Establish and implement multimodality treatment strategies for resectable, borderline resectable, and unresectable/locally advanced PCA, and discuss the importance of a multidisciplinary team approach
- Select the most appropriate therapy for individual patients with metastatic pancreatic ductal adenocarcinoma in the first-line setting and beyond progression
- Assess supportive care measures to ameliorate disease symptoms and treatment-related adverse events throughout the course of PCA management
- Describe the potential role of genomic profiling and evaluate novel treatment approaches in PCA including targeted therapy for DNA repair defects, stromal targeting agents, agents targeting abnormal metabolism in PCA cells, and immunotherapeutic strategies
This educational activity is supported by grants from Celgene, ERYTECH, RAFAEL Pharmaceuticals, and Shire.
Expert Practice in Pancreatic Cancer: Maximizing Patient Care With Innovation and Collaboration held in Vienna, Austria on 28–29 September 2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
Good CME Practice
This activity is provided by prIME Oncology.
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.